- GIAn tapahtumat
- Näkemyksiä ja analyysejä
- GIA yrityksenä
- Ura GIAssa
Get a snapshot of the top industry news from the Asia Pacific by email every two weeks. Subscriptions available here.
Source: The Straits Times, 22 February 2012
Singapore's booming health-care sector is luring private equity firms hungry for high-growth assets. Investors see huge potential in the industry, given that rising wealth creation is making care more affordable while the country's increasingly ageing population is driving demand.
Several factors strengthen the investment case of the private health-care sector in Singapore, not least demographics. An analyst said the defensive nature of hospital stocks also makes them attractive investments in the current volatile equity market.
Source: The Australian Financial Review, 11 February 2012
The value of private equity exits doubled in 201011 to $1.4 billion, as funds took advantage of a peak in prices during the financial year. The increase in trade sales, initial public offerings and buybacks by venture capital and private equity funds was up from $686 million in 2009, data from the Australian Bureau of Statistics show.
Industry players say the jump is due to a few large transactions, such as CHAMP Private Equity's $660 million sale of its majority share in higher education provider Study Group.However, in the midmarket, it also reflects a brief window of opportunity where valuations peaked on the back of a shortlived sharemarket rally.
Source: Business Line, 10 February 2012
In India, venture capital funding for biotech sector still remains in short supply, said Ms Terri Bresenham President & CEO of GE Healthcare India and Managing Director of Wipro GE Healthcare. Speaking at the ‘Bangalore India Bio 2012,' Ms Bresenham said, “With our experience of developing low cost medical devices from India, there is tremendous opportunities our here.”
“But there is huge gap between entrepreneurial skill and future capabilities. This has to be addressed immediately by both government and private sector to build a healthy base,” she added. Highlighting the global opportunities which India can grab in the Bio Similar space, Ms Bresenham said “here about 45 drugs worth $75 billion are to lose patent in the next eight years and again in bio-pharma $150 billion potential business opportunities by 2015.”
Visit our Private Equity practice